Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

Plus, check out our handy semaglutide weight loss dosage chart for an easy-to-follow overview ... 1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

The company said last month that it expected to report sales of diabetes drug Mounjaro and weight-loss treatment Zepbound below analysts' expectations for a second quarter in a row. The US ...

The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...